Jonathan Levenson

Company: FireCyte Therapeutics

Job title: Chief Scientific Officer

Seminars:

IGFBPL1-Fusion Proteins: A Multi-targeted Approach for Retina that Promotes Neuroprotection & Mitigates Neuroinflammation 2:10 pm

Introducing IGFBPL1 and its interactions with two validated neuroscience targets: SORT1 and DCC/Netrin-1 receptor Discussing IGFBPL1-fusion proteins as first-in-class therapeutics being developed for glaucoma, Dry-AMD/GA, and other optic neuropathies, exhibiting both direct neuroprotective and anti-inflammatory pharmacologies Sharing IGFBPL1-based platform and its significant opportunity in neurodegenerative disorders of the brainRead more

day: Day Two